Amiko Digital Health, a London-based developer of digital health tools powered by artificial intelligence, received a CE Mark for its Respiro medication sensors for use with inhalers from three different pharmaceutical companies.

The new certificate allows for the devices to be integrated in the EU into Teva's Spiromax inhaler, Chiesi's Nexthaler inhaler, and GlaxoSmithKline's Ellipta inhaler.

The Respiro platform features inhaler sensors designed to automatically capture patient monitoring data, such as “when and how well patients use their medication,” Amiko said.